New pill shows promise in quieting MS brain lesions
NCT ID NCT05119569
First seen Nov 11, 2025 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease activity and control relapses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Lou Ruvo
Las Vegas, Nevada, 89106, United States
-
Clinical Center Nis
Niš, 18000, Serbia
-
Clinical Center of Serbia
Belgrade, 11000, Serbia
-
Clinical Hospital Center Rijeka - PPDS
Rijeka, 51000, Croatia
-
Clinical Hospital Centre Zemun
Zemun, 11080, Serbia
-
Clinical center Kragujevac
Kragujevac, 34000, Serbia
-
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05, Czechia
-
Fakultni nemocnice u sv. Anny v Brne
Brno, 656 91, Czechia
-
Fullerton Neurology and Headache Center
Fullerton, California, 92835, United States
-
General Hospital Varazdin
Varaždin, 42000, Croatia
-
Klinicki bolnicki centar Zagreb
Zagreb, 10000, Croatia
-
Military Medical Academy
Belgrade, 11040, Serbia
-
Nemocnice Jihlava
Jihlava, 58633, Czechia
-
Poliklinika Solmed
Zagreb, 10000, Croatia
-
University Clinical Centre of the Republic of Srpska
Banja Luka, 78000, Bosnia and Herzegovina
-
Univerzitna nemocnica Bratislava
Bratislava, 821 01, Slovakia
-
Vseobecna Fakultni Nemocnice V Praze - CRC - PPDS
Prague, 128 08, Czechia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fenebrutinib (an oral drug that targets immune cells)
What this could lead to
If successful, this could point toward a new oral treatment option to reduce brain lesions and control relapses in multiple sclerosis.
What could go wrong
This is an early Phase 2 trial with only 109 participants, so results may not hold in larger studies. The drug may not outperform existing treatments or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.